Abstract
Tumor necrosis factor-α (TNF-α) is a pleiotropic cytokine that has important roles in various inflammatory disease in dermatology, including psoriasis, hidradenitis suppurativa, neutrophilic dermatoses, sarcoidosis, granuloma annulare, toxic epidermal necrolysis, Behçet disease, pityriasis rubra pilaris, scleroderma and sclerosis systemic, and erythema nodosum leprosum. Therefore, TNF-a inhibitor can be a therapeutic strategy to inhibit the progression of the disease. There are five TNF-α inhibitors that have been clinically investigated, such as etanercept, adalimumab, certolizumab pegol, infliximab, and golimumab. Each drug has different pharmacological profile, indication, and efficacy for different kind of diseases. However, TNF-α inhibitor also has several potential local or systemic side effects, including paradoxically increasing the risk of psoriasis.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
